Balstilimab (NCT06780787)

Name: Balstilimab trial for Rectal Adenocarcinoma (NCT06780787)
Uploaded: 2026-10-31T22:39:31.467Z
Duration: 1 min 19 s
Description: Balstilimab trial for Rectal Adenocarcinoma (NCT06780787). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06780787.

FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery: a one-minute explainerNCT067807871 min

Balstilimab trial for Rectal Adenocarcinoma (NCT06780787). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with untreated rectal adenocarcinoma that is T3N0 or node-positive, without distant spread. MRI must show a clear surgical margin and limited enlarged nodes.

The idea: FOLFOX chemotherapy joins botensilimab and balstilimab, which block CTLA4 and PD1 immune brakes. Treatment uses two-week cycles, with botensilimab only in cycles one and four. Complete responders may continue balstilimab alone; others may receive radiation with capecitabine. Researchers measure complete response and safety.

This phase 2 study plans 26 patients. Marwan Fakih leads at City of Hope, Duarte, the sole recruiting US site.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.